Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 18/20 | 0.55 |
| ▸ | CDK2 | P24941 | 18/20 | 0.55 |
| ▸ | CDK9 | P50750 | 18/20 | 0.55 |
| ▸ | CDK1 | P06493 | 18/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 17/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.55 |
| ▸ | CCND3 | P30281 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.55 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.55 |
| ▸ | CDK7 | P50613 | 14/20 | 0.53 |
| ▸ | CCNH | P51946 | 14/20 | 0.53 |
| ▸ | CDK4 | P11802 | 8/20 | 0.53 |
| ▸ | CCND1 | P24385 | 8/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430242 | 0.85 | CCNT1 (0.72) | CCNT1CDK2CDK9CDK1CCNB1 | |
| SCHEMBL11293278 | 0.84 | CCNT1 (0.55) | CCNT1CDK2CDK9CDK1CCNB1 | |
| SCHEMBL11294793 | 0.83 | CDK2 (0.57) | CCNT1CDK2CDK9CDK1CCNB1 | |
| SCHEMBL11293164 | 0.82 | CDK2 (0.54) | CCNT1CDK2CDK9CDK1CCNB1 | |
| SCHEMBL2436349 | 0.81 | CDK2 (0.54) | CCNT1CDK2CDK9CDK1CCNB1 | |
| SCHEMBL11296088 | 0.81 | CDK2 (0.58) | CCNT1CDK2CDK9CDK1CCNB1 | |
| SCHEMBL11295340 | 0.80 | CDK2 (0.55) | CCNT1CDK2CDK9CDK1CCNB1 | |
| SCHEMBL11297358 | 0.80 | CDK2 (0.62) | CCNT1CDK2CDK9CDK1CCNB1 | |
| SCHEMBL11294559 | 0.80 | CDK2 (0.52) | CCNT1CDK2CDK9CDK1CCNB1 | |
| SCHEMBL11297939 | 0.79 | CDK2 (0.51) | CCNT1CDK2CDK9CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288400-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-19 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017619-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-04 | — | — | US | disclosed |
| US-7700609-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-20 | — | — | US | disclosed |
| US-7700609-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280026-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CCNT1 957/4885CDK2 65/4885CDK9 138/4885 |
| US-20120183577-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K6 | CCNT1 957/4885CDK2 65/4885CDK9 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.